Description: OptiNose, Inc. is a pharmaceutical company. The Company is focused on the development and commercialization of products for patients treated by ear, nose and throat, or ENT, and allergy specialists. The Company’s products candidates include XHANCE (Nasal Polyps), XHANCE (Chornic Sinusitis) OPN-300, OPN-021, and other. The Company’s lead product, XHANCE (fluticasone propionate) nasal spray, utilizes breath powered exhalation delivery system (EDS), to deliver a topically acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. XHANCE has a differentiated clinical profile with the potential to become part of the standard of care for this disease because it is able to deliver medication to the primary site of inflammation
Home Page: www.optinose.com
OPTN Technical Analysis
1020 Stony Hill Road
Yardley,
PA
19067
United States
Phone:
267 364 3500
Officers
| Name | Title |
|---|---|
| Mr. Peter K. Miller | CEO & Director |
| Dr. Ramy A. Mahmoud M.D., M.P.H. | Pres & COO |
| Mr. Michael F. Marino Esq. | Chief Legal Officer & Corp. Sec. |
| Mr. Victor M. Clavelli | Chief Commercial Officer |
| Dr. Per Gisle Djupesland M.D., Ph.D. | Co-Founder & Chief Scientific Officer of OptiNose AS |
| Ms. Michele Janis MBA | VP & Acting CFO |
| Mr. Anthony Krick | VP & Chief Accounting Officer |
| Mr. Jonathan Neely | VP of Investor Relations & Bus. Operations |
| Ms. Karen E. Brophy | Chief HR Officer & VP of HR |
| Mr. John Messina | Sr. VP of Clinical Devel. & Medical Affairs |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 24.2559 |
| Price-to-Sales TTM: | 2.4666 |
| IPO Date: | 2017-10-13 |
| Fiscal Year End: | December |
| Full Time Employees: | 189 |